The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 424-426

  Sfakianos, Gregory P ^a   Numnum, T Michael ^a   Halverson, Caitlin B ^a   Panjeti, Deepa ^a   Kendrick IV, James E ^a   Straughn Jr , J Michael ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Avastin; Gastrointestinal fistula; Gastrointestinal perforation; Recurrent ovarian cancer; Retrospective cohort

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; COMPARATIVE STUDY; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; FEMALE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SURGERY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; HUMANS; INTESTINAL FISTULA; INTESTINAL PERFORATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 67651146348     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.05.031     Document Type: Article

References (18)

1. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21 (2003) 60-65
2. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. NEJM 355 (2006) 2542-2550
3. Cohen M.H., Gootenberg J., Keegan P., et al. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12 (2007) 713-718
4. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. NEJM 357 (2007) 2666-2667
5. Yang J., Haworth L., Sherry R., Hwu P., Schwartzentruber D., Topalian S., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. NEJM 349 (2003) 427-434
6. Burger R.A., Sill M., Monk B.J., Greer B., and Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J. Clin. Oncol. 25 (2007) 5165-5171
7. Garcia A.A., Oza A.M., Hirte H., Fleming G., Tsao-Wei D., Roman L., et al. Interim report of a phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian and primary peritoneal carcinoma: a California Cancer Consortium trial. American Society of Clinical Oncology (2005)
8. Cannistra S.A., Matulonis U., Penson R., Wenham R., Armstrong D., Burger R.A., et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. American Society of Clinical Oncology (2006)
9. Friberg G., Oza A.M., Morgan R.J., Vokes E.E., Gandara D.R., and Fleming G.F. Bevacizumab plus erlotinib for patients with recurrent ovarian and fallopian tube cancer: Preliminary results of a multi-center phase II trial. American Society of Clinical Oncology (2006)
10. Wright J., Secord A., Numnum T., Rocconi R., Powell M., Berchuck A., et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int. J. Gyn. Cancer 18 (2008) 400-406
11. Cohn D., Valmadre S., Resnick K., Eaton L., Copeland L., and Fowler J. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol. 102 (2006) 134-139
12. Numnum T., Rocconi R., Whitworth J., and Barnes M. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol. Oncol. 102 (2006) 425-428
13. Sprigs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol. Oncol. 90 3 Pt 2 (2003) S39-S44
14. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 Suppl. 5 (2002) 20-28
15. Herzog T.J. Recurrent ovarian cancer: how important is it to treat to disease progression?. Clin. Cancer Res. 10 (2004) 7439-7449
16. Hurtwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEJM 350 (2004) 2335-2342
17. Aghajanian C. The role of bevacizumab in ovarian cancer - an evolving story. Gynecol. Oncol. 102 (2006) 131-133
18. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol. 26 (2008) 76-82